Discovering The Role of IGHG2 in Human Immunity and Disease (G3501)

Target Name: IGHG2

NCBI ID: G3501

IGHG2

Other Name(s): DKFZp686I04196 | Immunoglobulin heavy constant gamma 2 (G2m marker) | immunoglobulin heavy constant gamma 2 (G2m marker)

Discovering The Role of IGHG2 in Human Immunity and Disease

IGHG2 (Immunoglobulin Heavy Chain Second Subunit) is a protein that is expressed in most tissues of the human body. It is a component of the immune system and plays a crucial role in the body's defense against infections and diseases. IGHG2 is also known as DKFZp686I04196, a gene that encodes for this protein.

IGHG2 is a glycoprotein which consists of four polypeptide chains. Each chain has a different function in the immune response. The first chain is known as heavy chain, the second chain is known as light chain, the third chain is known as middle chain, and the fourth chain is known as C chain. The heavy chain is the largest and consists of five constant (C) regions and one variable (V) region. The light chain is the second largest and consists of three constant (C) regions and one variable (V) region. The middle chain is the smallest and consists of four variable (V) regions. The C chain is the shortest and consists of one variable (V) region.

IGHG2 is a type of immunoglobulin or antibody, which is a protein produced by B cells in the immune system. It is one of the five classes of antibodies produced by B cells, along with IgM, IgG, IgA, IgE, and IgD. IgH2 is the third most abundant class of antibodies produced by B cells.

IGHG2 plays a crucial role in the immune response by providing the body with antibodies that help to neutralize or destroy pathogens such as viruses and bacteria. It is also involved in regulating the immune response by controlling the activity of other immune cells.

Research has suggested that IGHG2 may be a potential drug target or biomarker for several diseases, including systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects millions of people worldwide, and multiple sclerosis (MS), a progressive autoimmune disease that can cause muscle weakness, fatigue, and vision problems.

One of the reasons for the potential drug targeting of IGHG2 is its role in the development and progression of SLE. SLE is an autoimmune disease in which the immune system attacks the body's own tissues, including the skin, joints, organs, and blood vessels. IGHG2 has been shown to be involved in the development and progression of SLE by regulating the activity of immune cells and promoting the production of antibodies that contribute to the immune response.

Another potential drug target for IGHG2 is its role in the development and progression of MS. MS is an autoimmune disease that can cause muscle weakness, fatigue, and vision problems. IGHG2 has been shown to be involved in the development and progression of MS by regulating the activity of immune cells and promoting the production of antibodies that contribute to the immune response.

IGHG2 has also been shown to be involved in the development and progression of other autoimmune diseases, including rheumatoid arthritis (RA), psoriasis, and autoimmune haemolytic anemia.

In addition to its potential role in the immune response, IGHG2 has also been shown to have several potential therapeutic benefits. For example, it has been shown to have anti-inflammatory properties by regulating the production of pro-inflammatory cytokines. shown to have anti-tumor properties by promoting the production of anti-tumor antibodies and by inhibiting the growth of cancer cells.

Overall, IGHG2 is a protein that plays a crucial role in the immune system and has been shown to be involved in the development and progression of several autoimmune diseases. Further research is needed to determine its potential as a drug target or biomarker

Protein Name: Immunoglobulin Heavy Constant Gamma 2 (G2m Marker)

Functions: Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGHG2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHG2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets